Wall Street Analyst Sees 320% Upside Potential in DarioHealth Stock

Wall Street analyst Theodore O'Neill of Litchfield Hills Research reiterates his Buy rating and $3 price target on DarioHealth Corp. (NASDAQ: DRIO), highlighting 320% upside potential from current trading levels around $0.71. The analyst emphasizes DarioHealth's recent clinical findings validating its value proposition and strategic partnerships expanding its addressable market, particularly in the GLP-1 and sleep apnea markets. The valuation discount compared to peers is significant, with a fair value of $3 per share calculated using a discounted future earnings model and comparative peer analysis.